CHEK2 variants are found in fewer than one percent of the general population (0.61% in the Exome Aggregation Consortium) and in two percent of men with metastatic prostate cancer, giving a relative risk for metastatic prostate cancer of 3.1 (95% CI: 1.5–5.6), p = 0.000256. The gene discussed is CHEK2; the disease is metastatic prostate carcinoma.